Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | TYMP | P19971 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | UNG | P13051 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | TPO | P07202 | 1/20 | 0.35 |
| ▸ | LPO | P22079 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27721134 | 0.80 | SMN1; SMN2 (0.45) | GPR84SMN1; SMN2CA1TSHRTYMP | |
| SCHEMBL5071203 | 0.74 | GPR84 (0.60) | GPR84SMN1; SMN2CA1TSHRTYMP | |
| SCHEMBL2775601 | 0.71 | GPR84 (0.72) | GPR84SMN1; SMN2CA1TSHRHSD17B10 | |
| SCHEMBL4561073 | 0.70 | GPR84 (0.50) | GPR84SMN1; SMN2CA1TSHRTYMP | |
| SCHEMBL2959182 | 0.70 | GPR84 (0.50) | GPR84SMN1; SMN2CA1TSHRTYMP | |
| SCHEMBL18018476 | 0.70 | GPR84 (0.50) | GPR84SMN1; SMN2CA1TSHRTYMP | |
| SCHEMBL317706 | 0.70 | GPR84 (0.50) | GPR84SMN1; SMN2CA1TSHRTYMP | |
| SCHEMBL5508748 | 0.70 | GPR84 (0.50) | GPR84SMN1; SMN2CA1TSHRTYMP | |
| SCHEMBL6066218 | 0.70 | PDPK1 (0.54) | GPR84SMN1; SMN2CA1TSHRTYMP | |
| SCHEMBL11844328 | 0.70 | GPR84 (0.50) | GPR84SMN1; SMN2CA1TSHRTYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306623-A1 | PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-09-29 | — | — | US | disclosed |
| EP-3983409-A1 | PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2022-04-20 | — | — | EP | disclosed |
| CN-114008044-A | Pyridyl or pyrimidinyl MTOR kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2020249652-A1 | PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020249652-A1 | PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-17 | — | — | WO | disclosed |
| EP-2057140-B1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| EP-2176238-B1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | ASTRAZENECA AB (SE) | 2012-04-18 | — | — | EP | disclosed |
| US-8138183-B2 | Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K | ASTRAZENECA AB (SE) | 2012-03-20 | — | — | US | disclosed |
| US-8138183-B2 | Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K | ASTRAZENECA AB (SE) | 2012-03-20 | — | — | US | disclosed |
| US-8138183-B2 | Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K | ASTRAZENECA AB (SE) | 2012-03-20 | — | — | US | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| WO-2009007748-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| EP-1979325-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008023159-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007080382-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018134-A1 | Compounds - 945 | MTOR, PIK3CA, PIK3R5 | GPR84 3144/4885SMN1; SMN2 2003/4885CA1 3342/4885 |
| US-20080171743-A1 | Transcutaneous immunostimulation | NFATC1, TLR9, MTOR | GPR84 2452/4885SMN1; SMN2 2807/4885CA1 2479/4885 |
| US-20220306623-A1 | PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS | MTOR, RICTOR, RPTOR | GPR84 3449/4885SMN1; SMN2 2137/4885CA1 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.